Literature DB >> 16671461

Systemic zinc protoporphyrin administration reduces intracerebral hemorrhage-induced brain injury.

Y Gong1, H Tian, G Xi, R F Keep, J T Hoff, Y Hua.   

Abstract

Hemoglobin degradation products result in brain injury after intracerebral hemorrhage (ICH). Recent studies found that intracerebral infusion of heme oxygenase inhibitors reduces hemoglobin- and ICH-induced brain edema in rats and pigs. The present study examined whether systemic use of zinc protoporphyrin (ZnPP), a heme oxygenase inhibitor, can attenuate brain edema, behavioral deficits, and brain atrophy following ICH. All rats had intracerebral infusion of 100-microL autologous blood. ZnPP (1 nmol/hour/rat) or vehicle was given immediately or 6 hours following ICH. ZnPP was delivered intraperitoneally up to 14 days through an osmotic mini-pump. Rats were killed at day 3 and day 28 after ICH for brain edema and brain atrophy measurements, respectively. Behavioral tests were performed. We found that ZnPP attenuated brain edema in animals sacrificed 3 days after ICH (p < 0.05). ZnPP also reduced ICH-induced caudate atrophy (p < 0.05) and ventricular enlargement (p < 0.05). In addition, ZnPP given immediately or 6 hours after ICH improved neurological deficits (p < 0.05). In conclusion, systemic zinc protoporphyrin treatment started at 0 or 6 hours after ICH reduced brain edema, neurological deficits, and brain atrophy after ICH. These results indicate that heme oxygenase may be a new target for ICH therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16671461     DOI: 10.1007/3-211-30714-1_50

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  26 in total

1.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

2.  Astrocyte-specific heme oxygenase-1 hyperexpression attenuates heme-mediated oxidative injury.

Authors:  Luna Benvenisti-Zarom; Raymond F Regan
Journal:  Neurobiol Dis       Date:  2007-03-24       Impact factor: 5.996

3.  Heme oxygenase activity and hemoglobin neurotoxicity are attenuated by inhibitors of the MEK/ERK pathway.

Authors:  Jing Chen-Roetling; Zhi Li; Mai Chen; Olatilewa O Awe; Raymond F Regan
Journal:  Neuropharmacology       Date:  2009-02-06       Impact factor: 5.250

4.  Hemoglobin neurotoxicity is attenuated by inhibitors of the protein kinase CK2 independent of heme oxygenase activity.

Authors:  Jing Chen-Roetling; Zhi Li; Raymond F Regan
Journal:  Curr Neurovasc Res       Date:  2008-08       Impact factor: 1.990

5.  Targeting heme oxygenase after intracerebral hemorrhage.

Authors:  Jing Chen-Roetling; Xiangping Lu; Raymond F Regan
Journal:  Ther Targets Neurol Dis       Date:  2015-01-03

6.  Nrf2 to pre-condition the brain against injury caused by products of hemolysis after ICH.

Authors:  Xiurong Zhao; Jaroslaw Aronowski
Journal:  Transl Stroke Res       Date:  2013-02       Impact factor: 6.829

7.  Role of hemoglobin and iron in hydrocephalus after neonatal intraventricular hemorrhage.

Authors:  Jennifer M Strahle; Thomas Garton; Ahmad A Bazzi; Harish Kilaru; Hugh J L Garton; Cormac O Maher; Karin M Muraszko; Richard F Keep; Guohua Xi
Journal:  Neurosurgery       Date:  2014-12       Impact factor: 4.654

8.  Effect of heme oxygenase-1 on the vulnerability of astrocytes and neurons to hemoglobin.

Authors:  Jing Chen-Roetling; Raymond F Regan
Journal:  Biochem Biophys Res Commun       Date:  2006-09-18       Impact factor: 3.575

9.  Blood-brain barrier disruption and oxidative stress in guinea pig after systemic exposure to modified cell-free hemoglobin.

Authors:  Omer I Butt; Paul W Buehler; Felice D'Agnillo
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

10.  Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.

Authors:  Masanobu Okauchi; Ya Hua; Richard F Keep; Lewis B Morgenstern; Guohua Xi
Journal:  Stroke       Date:  2009-03-12       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.